NervGen Pharma Spotlights Spinal Injury Treatment
Company Announcements

NervGen Pharma Spotlights Spinal Injury Treatment

Story Highlights

NervGen Pharma (TSE:NGEN) has released an update.

NervGen Pharma, a clinical-stage biotech firm focusing on nervous system repair, has announced that its Chief Medical Officer will present at the U2FP 19th Annual Science & Advocacy Symposium. The presentation will discuss the challenges of translating spinal cord injury treatments from animal models to human clinical trials. NervGen holds exclusive rights to NVG-291, a peptide showing promise in nervous system repair, and is conducting a Phase 1b/2a trial to assess its efficacy in spinal cord injury recovery.

For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskNervGen Pharma to Present Innovative Treatments
TipRanks Canadian Auto-Generated NewsdeskNervGen Pharma Advances Spinal Injury Treatment Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App